While the ultimate outcome remains far from certain, the study is a bright spot—if a tenuous one—in the search for a treatment for Alzheimer’s, where more than 100 experimental drugs have failed.
The pharmaceutical company said the 130,000-square-foot building will allow scientists to collaborate better on research for small molecules and synthetic peptides.
An independent data-monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease.
The Indianapolis-based drugmaker has been working for years to develop the much-anticipated drug, which some analysts had said might ring up $2 billion a year in sales.
New therapies that could cure diseases caused by defective genes will get quicker approval from U.S. regulators, part of an effort by the Food and Drug Administration to keep pace with one of biotechnology’s fastest-growing fields.
The Indiana Clinical and Translational Sciences Institute said Tuesday morning it was chosen to receive the grant from the National Institutes for Health to fund its work in improving the health and economy of Indiana.
An Ohio-based animal rights group is calling on the Indiana University School of Medicine to fire staffers the group alleges violated laboratory protocols that resulted in the deaths of more than 100 lab animals.
The money is designed to further the work of Dr. Burcin Ekser and his team, who are working to print three-dimensional pig liver tissue from genetically engineered pig liver cells.
The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
The funds includes $7.6 million to study early-onset Alzheimer’s disease, $5.2 million to fund a clinical and translational sciences institute, and $4.8 million to fund epidemiologic databases to evaluate AIDS care in Africa.
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
A fight over whether Indiana should legalize medical marijuana seems all but inevitable now.
The study will focus on early-onset Alzheimer’s disease, which are about 5 percent of patients.
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact—and to finally customize ways to prevent and treat disease. Why does one sibling get sick but not another? Why does a drug […]
Researchers at Indiana University and Purdue University have received $2.55 million from Susan G. Komen to study possible new treatments.
The federal agency says the Indianapolis doctor studying Pfizer’s Chantix last year failed to keep accurate records and used patients who didn’t meet the trial requirements.
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
One of the bill’s author said it is designed to help parents who are “up against a wall,” and he stressed that it should not be confused as a first step to medical marijuana legalization in the state.
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
